ADHD Stimulant Misuse Dropped But the Shortage Hurt Real Families
Last updated:
The headline reads as good news: misuse of ADHD stimulant medications among young adults under 30 fell by nearly half between 2016 and 2023, dropping from 7.5 percent to 3.7 percent. A new FDA-commissioned study in the Journal of Clinical Psychopharmacology confirmed the trend, and coverage largely called it a success.
But the same years produced the worst ADHD medication shortage in modern history. In 2022, the Drug Enforcement Administration tightened manufacturing quotas for stimulant medications. Amphetamine fill rates fell 11 percent in a single year. A national survey found that 71.5 percent of ADHD patients reported difficulty filling their prescriptions. Misuse fell — and so did access for children and families who genuinely needed the medication. Those are not the same story, and the coverage treated them as one.
TL;DR
A June 2026 study in the Journal of Clinical Psychopharmacology, commissioned by the FDA, found stimulant misuse among adults under 30 fell from 7.5 percent (2016) to 3.7 percent (2023).
The same years produced the worst ADHD medication shortage in modern U.S. history: DEA manufacturing quotas tightened in 2022, amphetamine fill rates fell 11 percent in a single year, and 71.5 percent of ADHD patients reported difficulty filling prescriptions.
Lead author Margaret Maglione noted the data cannot separate supply effects from behavioral change — meaning the drop in misuse may reflect reduced access, not reduced demand.
A quota-based regulatory instrument reduces both misuse and legitimate treatment simultaneously. The coverage counted one outcome and not the other.
Attention and executive function challenges in children can be supported through targeted cognitive skill-building alongside medication, not as a replacement for it.
A new FDA-commissioned study found ADHD stimulant misuse among young adults fell by nearly half between 2016 and 2023. But the same years produced the worst ADHD medication shortage in modern history. Here is what the good-news headline missed — and what it means for families navigating ADHD support.
Common questions
If ADHD stimulant misuse went down, doesn’t that mean the regulations worked?
Not necessarily. The study’s own authors note the data cannot separate supply effects from behavioral change. When DEA quotas tightened and amphetamine fill rates fell 11 percent in one year, 71.5 percent of ADHD patients reported difficulty filling legitimate prescriptions. When supply falls across the board, misuse falls — but so does treatment for children and adults who genuinely need the medication. Measuring only one outcome and not the other is how a supply failure gets called a policy success.
My child couldn’t get their ADHD medication filled for months. Is this related?
Very likely yes. The shortage, which intensified in 2022 and 2023, was driven by a combination of DEA manufacturing quota reductions and the expiration of pandemic-era telehealth prescribing rules. A national survey found 71.5 percent of ADHD patients experienced difficulty filling prescriptions during this period. If your child was affected, it is worth raising with your prescriber now — both the clinical impact and whether availability has improved for specific formulations in your area.
Is medication the only option for ADHD, or are there other approaches?
Medication, when appropriately prescribed, is one of the most evidence-backed interventions for ADHD — and for many children it is a significant part of what makes their school day workable. But the cognitive skills that medication supports — working memory, sustained attention, impulse regulation — can also be directly strengthened through targeted practice. Most families find the best outcomes come from combining consistent medication access with active skill-building, not choosing between them. The shortage made that choice feel forced. It shouldn’t be.
Can a screener help me understand my child’s ADHD-related challenges?
A screener or multi-system assessment can map which cognitive processing skills — working memory, auditory processing, processing speed, executive function — are strongest and which need support. That information helps families and schools build a targeted plan alongside whatever clinical treatment is in place. A screener is a starting point, not a diagnosis, and is not a substitute for a professional clinical evaluation. If your child needs an IEP, a 504 plan, or prescription medication, a formal clinical evaluation is the required route to those supports.
The FDA-commissioned review, published in the Journal of Clinical Psychopharmacology in June 2026, was led by Margaret Maglione, MPP, at the Keck School of Medicine at the University of Southern California. The research team analyzed data from the National Survey on Drug Use and Health, the federal government’s largest annual survey on substance use in the United States. The study tracked stimulant misuse rates — defined as using a prescription stimulant without a prescription, or using it differently than prescribed — among adults under 30 from 2016 through 2023.
The main finding: stimulant misuse among this age group fell from 7.5 percent in 2016 to 3.7 percent in 2023, with the drop concentrated in Adderall misuse. Lead author Margaret Maglione stated: “We found a rapid drop in misuse of these medications, largely driven by a decline in Adderall misuse among young adults. More recent data suggest that those lower rates have remained stable since 2023.”
The study also documented what was happening on the supply side during the same period. The DEA tightened manufacturing quotas for stimulant medications starting in 2022. Amphetamine fill rates fell 11 percent between 2022 and 2023 alone. Separately, pandemic-era telehealth prescribing rules that had allowed physicians to prescribe controlled substances without an in-person visit expired, further restricting access for patients who had been receiving care remotely. The FDA-commissioned researchers noted the data could not separate supply effects from behavioral change — meaning the study could not determine how much of the misuse drop reflected people choosing differently versus people who simply could not obtain the medication at all.
Author Quote"
We found a rapid drop in misuse of these medications, largely driven by a decline in Adderall misuse among young adults. More recent data suggest that those lower rates have remained stable since 2023.
"
What the coverage gets wrong
Most coverage of this Journal of Clinical Psychopharmacology study treats the stimulant misuse decline as confirmation that DEA quota tightening and the telehealth prescribing crackdown achieved their intended effect. What is absent from that framing: the study’s own authors note the data cannot separate supply effects from behavioral change. When supply falls by 11 percent and 71.5 percent of legitimate patients report difficulty accessing their medication, a reduction in measured misuse is an expected mathematical outcome — not necessarily evidence of changed behavior. A regulatory outcome that harms legitimate patients while reducing misuse is a tradeoff, not a win. Measuring only the win while leaving the tradeoff uncounted is what gets children left out of the headline.
Why a supply fall and a misuse fall are not the same policy win
The mechanism that reduced misuse and the mechanism that reduced legitimate treatment are the same mechanism: less medication in circulation. When DEA quotas tighten and pharmacy shelves run short, everyone who depends on stimulant prescriptions faces the same shortage — the college student misusing Adderall for exam performance, and the child whose attention regulation, classroom functioning, and emotional steadiness depend on a consistent medication supply. A quota-based instrument cannot distinguish between them.
A national patient survey conducted during the shortage found that 71.5 percent of ADHD patients reported difficulty filling their prescriptions. Families described calling pharmacy after pharmacy, driving hours to fill a prescription, or rationing doses when supplies ran short. Children who had been stable on medication for years experienced disrupted school performance, behavioral dysregulation, and intensified anxiety during the months when their medication was unavailable.
The attention and executive function skills that ADHD medication supports — working memory, impulse regulation, sustained focus — are the same skills that drive academic performance, emotional regulation, and social connection for children with ADHD. Disrupting medication access for months at a time is not a neutral event in a child’s development. The research measuring misuse did not measure those costs.
Key Takeaways:
1
Misuse fell, but so did supply: An FDA-commissioned study found stimulant misuse among young adults dropped from 7.5 percent to 3.7 percent between 2016 and 2023 — but the same period saw DEA quotas tighten and 71.5 percent of ADHD patients struggle to fill legitimate prescriptions.
2
Supply-side instruments cannot target misuse alone: When DEA quota cuts reduce the medication in circulation, the shortage hits legitimate patients and misusers equally. The study’s own authors note the data cannot separate supply effects from behavioral change.
3
Attention skills can be built alongside medication: Working memory, impulse regulation, and sustained focus — the cognitive systems ADHD medication supports — can also be strengthened through targeted skill-building, giving families more than one lever when access to medication becomes uncertain.
What families with ADHD children should take from this
Two things are true at once. Stimulant medications, when appropriately prescribed and consistently available, are among the most effective interventions for childhood ADHD — the evidence base is substantial and long-running. And attention challenges in children are rarely a single-system problem. The working memory difficulties, processing speed gaps, and executive function challenges that often accompany ADHD reflect cognitive processing systems that can also be strengthened through targeted practice alongside medication, not instead of it.
If your child has experienced medication access disruptions during the shortage period, this is worth raising directly with your prescriber — both the clinical impact and the options for maintaining consistent access, including whether a different formulation or schedule has better availability. The shortage has eased in some regions and worsened in others; the pattern is not uniform, and what was unavailable in 2023 may be available now.
A note on screeners and formal evaluation: a screener for learning or attention challenges is a starting point, not a diagnosis, and is not a substitute for a clinical ADHD evaluation. Formal diagnosis is the route to prescription medication, IEP or 504 accommodations, and clinical monitoring. What a multi-system assessment adds is a fuller picture of which cognitive processing skills are strongest and which need additional support — information that helps families and schools build a complete plan, not a label.
The enemy in this story is not a person or a party. It is a regulatory instrument — quota-based supply control — that cannot distinguish between a college student buying Adderall without a prescription and a twelve-year-old whose classroom performance, emotional regulation, and sense of self depend on consistent, reliable access to their medication. Blunt instruments produce blunt outcomes. Misuse fell, and so did treatment for the children who needed it most. Every family that spent 2022 calling pharmacy after pharmacy, rationing doses, and watching a child destabilize paid the cost of a policy that counted misuse down as a win without counting the families left out of the accounting.
Medication is one lever. It is not the only one. The attention and executive function skills at the heart of ADHD — the ability to hold a thought long enough to act on it, to filter out distraction, to sequence a multi-step task — can be directly strengthened through targeted practice, and they don’t go on backorder. Our free Learning Difficulties Analysis maps the cognitive processing systems connected to attention, focus, and working memory — not to replace medication when it’s needed, but because a complete picture of your child’s strengths and challenges gives you more than one way to help. It is a starting point, not a clinical diagnosis, and it does not replace a professional evaluation when formal accommodations are on the table.
Is Your Child Struggling in School?
Get Your FREE Personalized Learning Roadmap
Comprehensive assessment + instant access to research-backed strategies
